Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

FDA approves new indications for Zerit and Videx

Sep. 9, 1999

Two small-molecule anti-HIV compounds targeting gp41 identified at New York Blood Center

Sep. 9, 1999

Preliminary results of two Remune studies published in the Journal of Infectious Diseases

Sep. 9, 1999

More on Hughes Institute's new anti-HIV compounds with efficacy against resistant strains

Sep. 8, 1999

Growth hormone tested in HIV-positive patients with opportunistic infections

Sep. 8, 1999

Preparation and use of live HIV vaccine reported by Research Development Foundation

Sep. 7, 1999

Licensing opportunity from NIH: thioester compounds for inactivating HIV

Sep. 6, 1999

Chemokine receptor modulators designed at Merck & Co.

Sep. 2, 1999

AMD-3329 is a more potent derivative of the CXCR4 antagonist AMD-3100

Aug. 30, 1999

Bio-Technology General granted additional patent allowance for oxandrolone

Aug. 24, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...